Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
Primary Purpose
Pressure Ulcers, Spinal Cord Injury
Status
Terminated
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
HP011-101 (Xenaderm Ointment)
Standard Care
Sponsored by
About this trial
This is an interventional treatment trial for Pressure Ulcers focused on measuring Pressure Ulcers, Spinal Cord Injury, Healthpoint, Xenaderm, 011-101
Eligibility Criteria
Inclusion Criteria:
- Provide informed consent, or assent if less than 18 years of age.
- Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
- Have pressure ulcers ≤ Stage II severity, ≥ 2 cm² and ≤ 100 cm² in aggregate area (each area will be measured, including ulcer area (cm2), perimeter (cm) and greatest depth (cm) using the ARANZ Silhouette™ wound imaging and measurement device, and will remain at the treating facility for at least three weeks.
- In the opinion of the Investigator, are maintaining an adequate nutritional status and are receiving a full caloric diet, either orally or by tube.
- All female subjects must have a negative urinary pregnancy test at screening.
Have, within 12 weeks prior to screening, clinical laboratory test results indicating:
- Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels < 3x upper limit of the Healthpoint normal range
- HbA1C ≤ 12%
- Hemoglobin ≥ 8 g/dL
- Serum albumin, pre-albumin, and serum total protein measurements must be collected or obtained. These will serve as baseline covariates for analysis, but will not be used as inclusion criteria.
The most recently obtained laboratory values must be evaluated against the stated criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
- For ulcers that will require surgical debridement, any debridement modality may be used at baseline, but the ulcer must remain a Stage I or Stage II partial thickness wound after debridement.
- Have spinal cord injuries, which are motor complete or motor incomplete injuries that are based on American Spinal Injury Association (ASIA) Impairment classifications A, B, C, and D.
Exclusion Criteria:
- Have a spinal cord injury from, epidural abscess, infection, neurodegenerative process, or malignancy.
- Have a known hypersensitivity to any of the test articles or their components.
- Have received therapy with another investigational agent within thirty (30) days of screening.
- Are pregnant or nursing.
- Have received systemic treatment with glucocorticoids for > 10 consecutive days within 1 week prior to the start of the study.
- Have received chemotherapy or radiation therapy within the past 5 years.
- Have clinical evidence of bacterial or fungal infection of the any open wound per visual/clinical assessment.
- Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
- Have had documented osteomyelitis in the ulcer area within 6 months prior to screening.
- Have end-stage renal disease, are receiving treatment for cancer (except for non-melanoma skin cancer within the past five years), or untreated peripheral vascular disease.
Sites / Locations
- VA Medical Center, Long Beach
- Santa Clara Valley Medical Center
- James A. Haley Veterans Hospital, Tampa
- Kessler Institute for Rehabilitation
- Carolinas Research
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
HP011-101
Various
Arm Description
Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
Outcomes
Primary Outcome Measures
Change From Baseline in Composite PUSH (Pressure Ulcer Scale for Healing) Score
Change from baseline in composite wound bed scores measured as the PUSH total score on Day 15. The PUSH Tool v.3.0, which monitors the three critical parameters that are the most indicative of healing, was used in this study. Scales for the three measurements were: Area = 0 (healthy skin) to 10 (>24 cm x cm); Exudate = 0 (non) to 3 (heavy); Tissue type = 0 (epithelial tissue) to 4 (necrotic tissue). All values were summed and final values are the cumulative scores.
Cumulative Scores = 0 (Best possible outcome: healthy skin/epithelial tissue with no exudate) to 17 (Worst possible outcome: wound >24 cm x cm, containing necrotic tissue, with heavy exudate)
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01433159
Brief Title
Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
Official Title
Comparison of HP011-101 to Standard Care in the Management of Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
Study Type
Interventional
2. Study Status
Record Verification Date
January 2014
Overall Recruitment Status
Terminated
Why Stopped
Business decision
Study Start Date
September 2011 (undefined)
Primary Completion Date
January 2013 (Actual)
Study Completion Date
January 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Healthpoint
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The trial will compare the effects of 14 days treatment with HP011 101 versus Standard Care in subjects with Stage I or II pressure ulcers as a complication of spinal cord injury, measured as change from baseline in composite wound bed scores of the PUSH 3.0 tool.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pressure Ulcers, Spinal Cord Injury
Keywords
Pressure Ulcers, Spinal Cord Injury, Healthpoint, Xenaderm, 011-101
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
19 (Actual)
8. Arms, Groups, and Interventions
Arm Title
HP011-101
Arm Type
Experimental
Arm Title
Various
Arm Type
Active Comparator
Arm Description
Standard Care at each site other than Xenaderm Ointment or other BCT-containing products
Intervention Type
Drug
Intervention Name(s)
HP011-101 (Xenaderm Ointment)
Intervention Description
The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
Intervention Type
Drug
Intervention Name(s)
Standard Care
Intervention Description
No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
Primary Outcome Measure Information:
Title
Change From Baseline in Composite PUSH (Pressure Ulcer Scale for Healing) Score
Description
Change from baseline in composite wound bed scores measured as the PUSH total score on Day 15. The PUSH Tool v.3.0, which monitors the three critical parameters that are the most indicative of healing, was used in this study. Scales for the three measurements were: Area = 0 (healthy skin) to 10 (>24 cm x cm); Exudate = 0 (non) to 3 (heavy); Tissue type = 0 (epithelial tissue) to 4 (necrotic tissue). All values were summed and final values are the cumulative scores.
Cumulative Scores = 0 (Best possible outcome: healthy skin/epithelial tissue with no exudate) to 17 (Worst possible outcome: wound >24 cm x cm, containing necrotic tissue, with heavy exudate)
Time Frame
baseline, 14 Days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
12 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Provide informed consent, or assent if less than 18 years of age.
Age 12 years or older, of either sex, and of any race or skin type, provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
Have pressure ulcers ≤ Stage II severity, ≥ 2 cm² and ≤ 100 cm² in aggregate area (each area will be measured, including ulcer area (cm2), perimeter (cm) and greatest depth (cm) using the ARANZ Silhouette™ wound imaging and measurement device, and will remain at the treating facility for at least three weeks.
In the opinion of the Investigator, are maintaining an adequate nutritional status and are receiving a full caloric diet, either orally or by tube.
All female subjects must have a negative urinary pregnancy test at screening.
Have, within 12 weeks prior to screening, clinical laboratory test results indicating:
Alkaline phosphatase, ALT, AST, BUN and serum creatinine levels < 3x upper limit of the Healthpoint normal range
HbA1C ≤ 12%
Hemoglobin ≥ 8 g/dL
Serum albumin, pre-albumin, and serum total protein measurements must be collected or obtained. These will serve as baseline covariates for analysis, but will not be used as inclusion criteria.
The most recently obtained laboratory values must be evaluated against the stated criteria. If these values are not available from a blood sample within 12 weeks of screening, blood must be drawn at screening and these laboratory values determined.
For ulcers that will require surgical debridement, any debridement modality may be used at baseline, but the ulcer must remain a Stage I or Stage II partial thickness wound after debridement.
Have spinal cord injuries, which are motor complete or motor incomplete injuries that are based on American Spinal Injury Association (ASIA) Impairment classifications A, B, C, and D.
Exclusion Criteria:
Have a spinal cord injury from, epidural abscess, infection, neurodegenerative process, or malignancy.
Have a known hypersensitivity to any of the test articles or their components.
Have received therapy with another investigational agent within thirty (30) days of screening.
Are pregnant or nursing.
Have received systemic treatment with glucocorticoids for > 10 consecutive days within 1 week prior to the start of the study.
Have received chemotherapy or radiation therapy within the past 5 years.
Have clinical evidence of bacterial or fungal infection of the any open wound per visual/clinical assessment.
Have a severe burn, immunodeficiency disorder, hematologic disorder, or metastatic malignancy.
Have had documented osteomyelitis in the ulcer area within 6 months prior to screening.
Have end-stage renal disease, are receiving treatment for cancer (except for non-melanoma skin cancer within the past five years), or untreated peripheral vascular disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Herbert B Slade, MD
Organizational Affiliation
Healthpoint
Official's Role
Study Chair
Facility Information:
Facility Name
VA Medical Center, Long Beach
City
Long Beach
State/Province
California
ZIP/Postal Code
90822
Country
United States
Facility Name
Santa Clara Valley Medical Center
City
San Jose
State/Province
California
ZIP/Postal Code
95128
Country
United States
Facility Name
James A. Haley Veterans Hospital, Tampa
City
Tampa
State/Province
Florida
ZIP/Postal Code
33612
Country
United States
Facility Name
Kessler Institute for Rehabilitation
City
West Orange
State/Province
New Jersey
ZIP/Postal Code
07052
Country
United States
Facility Name
Carolinas Research
City
Charlotte
State/Province
North Carolina
ZIP/Postal Code
28203
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Comparison of HP011-101 to Standard Care for Stage I-II Pressure Ulcers in Subjects With Spinal Cord Injury
We'll reach out to this number within 24 hrs